AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23098887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (educational programme encouraging physical activity and healthy nutrition, provision of bicycles)
Number of subjects: 173
Study 23098887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 173
Study 23098887 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 173
Study 22087616 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (20-minute massage by parents at home before bedtime every night for 5 weeks, in addition to standard asthma treatment)
Number of subjects: 60
Study 22087616 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard asthma treatment alone for 5 weeks)
Number of subjects: 60
Study 18215682 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaket and MTA
Number of subjects: 108
Study 18215682 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus and MTA
Number of subjects: 108
Study 18215682 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaket and amalgam
Number of subjects: 108
Study 18215682 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus and amalgam
Number of subjects: 108
Study 18215682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Endo and MTA
Number of subjects: 108
Study 18215682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Endo and amalgam
Number of subjects: 108
Study 18215682 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 108
Study 16638253 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori serology testing
Number of subjects: 47
Study 16638253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no H. pylori testing)
Number of subjects: 47
Study 14673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 3597
Study 14673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole cyclodextrine solution
Number of subjects: 3597
Study 14673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules
Number of subjects: 3597
Study 14673051 — intervention group
Group type: COMPARATOR
Intervention: Control without cyclodextrine
Number of subjects: 3597
Study 14673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 3597
Study 14673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 3597
Study 10817039 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (n = 16; median volume 102 ml; 95% confidence interval 90‐108 ml)
Number of subjects: 31
Study 10817039 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (n = 15; median volume 105 ml; 95% confidence interval 95‐114 ml)
Number of subjects: 31
Study 9179339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Number of subjects: 72
Study 9179339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 72
Study 1556414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 2 g b.i.d.
Number of subjects: 55
Study 1556414 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.i.d.
Number of subjects: 55
Study 3932570 — intervention group
Group type: EXPERIMENTAL
Intervention: Proluton, 50‐mg daily injections given on days 7‐16 following oocyte recovery
Number of subjects: 186
Study 3932570 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 186
Study 31838377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (SS) 400 μg elemental Se, taken orally daily for 8 weeks
Number of subjects: 24
Study 31838377 — intervention group
Group type: EXPERIMENTAL
Intervention: Se‐methylselenocysteine (MSC) 400 μg elemental Se, taken orally daily for 8 weeks
Number of subjects: 24
Study 31838377 — intervention group
Group type: EXPERIMENTAL
Intervention: Seleno‐l‐methionine (SLM) 400 μg elemental Se, taken orally daily for 8 weeks
Number of subjects: 24
Study 31113455 — intervention group
Group type: EXPERIMENTAL
Intervention: LBEC0101 (50 mg) administered subcutaneously once per week for 48 weeks
Number of subjects: 148
Study 27776217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepicol (pysllium fibre, inulin and 5 probiotic strains)
Number of subjects: 69
Study 27776217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 25602128 — intervention group
Group type: EXPERIMENTAL
Intervention: FDIS+MET
Number of subjects: 184
Study 25602128 — intervention group
Group type: COMPARATOR
Intervention: FDIS+placebo
Number of subjects: 184
Study 25602128 — intervention group
Group type: COMPARATOR
Intervention: SRP+MET
Number of subjects: 184
Study 25602128 — intervention group
Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 184
Study 23723446 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS) algorithm ON
Number of subjects: 50
Study 23723446 — intervention group
Group type: COMPARATOR
Intervention: Closed-loop stimulation (CLS) algorithm OFF
Number of subjects: 50
Study 21843000 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit believability in health condition
Number of subjects: 306
Study 21843000 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit believability in appearance condition
Number of subjects: 306
Study 21843000 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit believability in health condition
Number of subjects: 306
Study 21843000 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought-listing valence index in both conditions
Number of subjects: 306
Study 18953265 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 309
Study 18953265 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 309
Study 18182867 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Surface Warming (SSW)
Number of subjects: 60
Study 18182867 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Fluid Warming (IFW)
Number of subjects: 60
Study 12557133 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg daily
Number of subjects: 8076
Study 12557133 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 8076
Study 18425649 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational approach
Number of subjects: 150
Study 18425649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive approach
Number of subjects: 150
Study 18425649 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 150
Study 8778866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg) during a nap
Number of subjects: 12
Study 8778866 — intervention group
Group type: COMPARATOR
Intervention: Placebo during a nap
Number of subjects: 12
Study 1873773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus doxorubicin (60 mg/m2 every 3 to 4 weeks)
Number of subjects: 82
Study 1873773 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion doxorubicin (60 mg/m2 every 3 to 4 weeks)
Number of subjects: 82
Study 1873773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus doxorubicin
Number of subjects: 82
Study 1873773 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion doxorubicin
Number of subjects: 82
Study 6131529 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 55
Study 6131529 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocking agents
Number of subjects: 55
Study 6131529 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 55
Study 6729548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg by mouth b.i.d. X 30 doses)
Number of subjects: 50
Study 6729548 — intervention group
Group type: COMPARATOR
Intervention: Breast binders
Number of subjects: 50
Study 28752937 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy (ICBT)
Number of subjects: 61
Study 28752937 — intervention group
Group type: COMPARATOR
Intervention: Traditional logistic regression
Number of subjects: 61
Study 26813033 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy (QOLT)
Number of subjects: 60
Study 26813033 — intervention group
Group type: COMPARATOR
Intervention: Heart Healthy Education
Number of subjects: 60
Study 23893353 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 25
Study 22365864 — intervention group
Group type: EXPERIMENTAL
Intervention: Box training with additional practice (Group 3)
Number of subjects: 41
Study 22365864 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental training (Group 5)
Number of subjects: 41
Study 22365864 — intervention group
Group type: EXPERIMENTAL
Intervention: VRS training (Group 4)
Number of subjects: 41
Study 22365864 — intervention group
Group type: EXPERIMENTAL
Intervention: Box training (Group 2 and 3)
Number of subjects: 41
Study 22365864 — intervention group
Group type: EXPERIMENTAL
Intervention: Box training (Group 3)
Number of subjects: 41
Study 22365864 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 41
Study 20507655 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and psychological intervention
Number of subjects: 374
Study 18499368 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT), n=22, 16 weeks duration, 60-80% 1RM
Number of subjects: 43
Study 18499368 — intervention group
Group type: COMPARATOR
Intervention: Not trained control (CT), n=21
Number of subjects: 43
Study 15623816 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 mg sc twice a day over 12 wk)
Number of subjects: 31
Study 12925474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propacetamol 30 mg kg(‐1) and diclofenac 1.1 mg kg(‐1)
Number of subjects: 10
Study 12925474 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 1.1 mg kg(‐1) alone
Number of subjects: 10
Study 12925474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 10
Study 10822120 — intervention group
Group type: EXPERIMENTAL
Intervention: leaflet
Number of subjects: 415
Study 10822120 — intervention group
Group type: EXPERIMENTAL
Intervention: brochure
Number of subjects: 415
Study 10822120 — intervention group
Group type: EXPERIMENTAL
Intervention: booklet
Number of subjects: 415
Study 10822120 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 415
Study 8630955 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MEG) 160 mg daily
Number of subjects: 266
Study 8630955 — intervention group
Group type: COMPARATOR
Intervention: Premarin (PRE) 1.25 mg/day for the first 3 days of a 14 day cycle followed by Megestrol acetate (PRE/MEG)
Number of subjects: 266
Study 8630955 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MEG)
Number of subjects: 266
Study 8630955 — intervention group
Group type: COMPARATOR
Intervention: Premarin and Megestrol acetate (PRE/MEG)
Number of subjects: 266
Study 1737157 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg intravenously immediately, then three doses of 40 mg intravenously at eight hourly intervals, then 40 mg orally at 12 hourly intervals for four days
Number of subjects: 1147
Study 1737157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1147
Study 6884411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphinpyrazone 800 mg daily
Number of subjects: 28
Study 6884411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31642690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 20138
Study 30229370 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with opioid analgesia (GA)
Number of subjects: 20
Study 30229370 — intervention group
Group type: COMPARATOR
Intervention: Propofol-paravertebral anesthetic with continuing analgesia (PPA)
Number of subjects: 20
Study 26551216 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment support group (n = 56)
Number of subjects: 122
Study 26551216 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 66)
Number of subjects: 122
Study 24732311 — intervention group
Group type: EXPERIMENTAL
Intervention: MnSOD transcript level in patients with diabetes (both with and without microvascular complications)
Number of subjects: 46
Study 24732311 — intervention group
Group type: EXPERIMENTAL
Intervention: MnSOD protein level in patients without microvascular complications
Number of subjects: 46
Study 24732311 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MnSOD expression with fasting plasma glucose and total cholesterol levels
Number of subjects: 46
Study 21960371 — intervention group
Group type: COMPARATOR
Intervention: Stented group
Number of subjects: 156
Study 21960371 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-stented group
Number of subjects: 156
Study 20472045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency ultrasound (US) applied during 5 min with a 36 kHz probe, pulsed mode (2s on/5s off), intensity of 2.72 W/cm², with betamethasone 17-valerate cream, 2-hour occlusion.
Number of subjects: 15
Study 20472045 — intervention group
Group type: COMPARATOR
Intervention: Topical steroids with 1-hour occlusion.
Number of subjects: 15
Study 20472045 — intervention group
Group type: COMPARATOR
Intervention: Massage alone (control group).
Number of subjects: 15
Study 20472045 — intervention group
Group type: COMPARATOR
Intervention: Topical steroids with 2-hour occlusion (without US).
Number of subjects: 15
Study 18630537 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with massage of sole and oral administration of Alprazolam
Number of subjects: 58
Study 18630537 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (control group)
Number of subjects: 58
Study 18630537 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with massage of sole
Number of subjects: 58
Study 16049630 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 174
Study 16049630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance/flexibility training
Number of subjects: 174
Study 11813825 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP) therapy
Number of subjects: 71
Study 11813825 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (inactive-CP)
Number of subjects: 71
Study 10379017 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids (8-week course)
Number of subjects: 271
Study 10379017 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids (2-week course)
Number of subjects: 271
Study 10379017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 10379017 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids (combined groups)
Number of subjects: 271
Study 10379017 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids
Number of subjects: 271
Study 7554626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral component
Number of subjects: 0
Study 7554626 — intervention group
Group type: COMPARATOR
Intervention: Noncemented femoral component
Number of subjects: 0
Study 7554626 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (1000 units)
Number of subjects: 0
Study 7554626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented and noncemented femoral components
Number of subjects: 0
Study 1940960 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP‐choline
Number of subjects: 216
Study 1940960 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 216
Study 7104168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12
Study 7104168 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone 400 mg
Number of subjects: 12
Study 7104168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 12
Study 7104168 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 12
Study 31388638 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Number of subjects: 37
Study 31388638 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 37
Study 28188240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once daily before breakfast for 24 weeks
Number of subjects: 350
Study 28188240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 28188240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 350
Study 25694153 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior scleral reinforcement (PSR) combined with patching therapy
Number of subjects: 32
Study 25694153 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior scleral reinforcement (PSR)
Number of subjects: 32
Study 25694153 — intervention group
Group type: COMPARATOR
Intervention: Control group (contact lens wear and patching)
Number of subjects: 32
Study 23797498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinous process splitting decompression (LSPSD)
Number of subjects: 51
Study 23797498 — intervention group
Group type: COMPARATOR
Intervention: Conventional midline decompression
Number of subjects: 51
Study 23797498 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 51
Study 20945253 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month group-based diabetes prevention programme (The Healthy Living Course)
Number of subjects: 307
Study 20945253 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (standard care from GPs)
Number of subjects: 307
Study 19145002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium PD fluid with [Na+] = 115 mmol/l (group A)
Number of subjects: 25
Study 19145002 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium PD fluid with [Na+] = 102 mmol/l (group B)
Number of subjects: 25
Study 16887727 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine treatment
Number of subjects: 150
Study 16887727 — intervention group
Group type: COMPARATOR
Intervention: Previous audiometric studies
Number of subjects: 150
Study 15253711 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion in ESRD patients
Number of subjects: 0
Study 15253711 — intervention group
Group type: COMPARATOR
Intervention: Amino acid infusion in healthy controls
Number of subjects: 0
Study 15253711 — intervention group
Group type: EXPERIMENTAL
Intervention: Postabsorptive state in ESRD patients
Number of subjects: 0
Study 15253711 — intervention group
Group type: COMPARATOR
Intervention: Postabsorptive state in healthy controls
Number of subjects: 0
Study 11517199 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow Driver (IFD)
Number of subjects: 36
Study 9052418 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1600 mg daily) with antioestrogens
Number of subjects: 121
Study 9052418 — intervention group
Group type: COMPARATOR
Intervention: Antioestrogens only (20 mg tamoxifen or 60 mg toremifene daily)
Number of subjects: 121
Study 9052418 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 121
Study 9052418 — intervention group
Group type: COMPARATOR
Intervention: Toremifene
Number of subjects: 121
Study 7689752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion during OLT
Number of subjects: 0
Study 7689752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1 infusion)
Number of subjects: 0
Study 7689752 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PGE1 and control)
Number of subjects: 0
Study 3518529 — intervention group
Group type: EXPERIMENTAL
Intervention: extract adsorbed to aluminium hydroxide (Alutard‐SQ)
Number of subjects: 32
Study 3518529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmalgen extract
Number of subjects: 32
Study 3518529 — intervention group
Group type: EXPERIMENTAL
Intervention: non‐adsorbed extract from Allergologisk Laboratorium (ALK aq.)
Number of subjects: 32
Study 3518529 — intervention group
Group type: COMPARATOR
Intervention: All three extracts
Number of subjects: 32
Study 28856945 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf ankle-foot orthosis
Number of subjects: 139
Study 28856945 — intervention group
Group type: COMPARATOR
Intervention: Bespoke ankle-foot orthosis
Number of subjects: 139
Study 27020594 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (3-5 mg/kg i.v.)
Number of subjects: 50
Study 27020594 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (8% inhaled)
Number of subjects: 50
Study 25590336 — intervention group
Group type: EXPERIMENTAL
Intervention: GET.ON Recovery (internet-based recovery training)
Number of subjects: 128
Study 25590336 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control (WLC)
Number of subjects: 128
Study 23318391 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-Darc
Number of subjects: 35
Study 21320338 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic Q-potencies
Number of subjects: 228
Study 21320338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 19634966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for insomnia
Number of subjects: 57
Study 17244597 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function tests in farm workers
Number of subjects: 120
Study 17244597 — intervention group
Group type: COMPARATOR
Intervention: Olfactory function tests in non-farm controls
Number of subjects: 120
Study 17244597 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function tests after first day of working cycle
Number of subjects: 120
Study 17244597 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function tests on Day 5 for farm subjects
Number of subjects: 120
Study 15651516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml fentanyl
Number of subjects: 150
Study 15651516 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketamine
Number of subjects: 150
Study 15651516 — intervention group
Group type: COMPARATOR
Intervention: 2 ml normal saline (placebo)
Number of subjects: 150
Study 11705075 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaglobin (5 ml/kg/day for 3 days)
Number of subjects: 39
Study 11705075 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunoglobulins)
Number of subjects: 39